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SUMMARY. Significant liver disease has been reported in
chronic hepatitis B patients with normal alanine amino-
transferase (ALT) but most studies performed biopsies on
selected patients only. The aims of this study were to deter-
mine the rate of liver biopsy, characteristics of patients who
underwent a biopsy and factors associated with significant
liver disease in a cohort of such patients. Records of patients
with chronic hepatitis B during a 10-year period were
reviewed. Significant liver disease was defined as Knodell
HAI ‡ 7 and/or Ishak fibrosis ‡ 3. Of 743 patients, 55.7%
were Asian, 56.4% were men, and the mean age was
43.1 years. One hundred and ninety-three (26%) had
undergone a biopsy. Biopsied patients were more likely to be
men, HBeAg positive, and had lower platelet and higher
alkaline phosphatase, bilirubin, ALT and hepatitis B virus
(HBV) DNA. Significant liver disease was observed in 20% of
patients who had normal ALT at presentation, 14% of those
with normal ALT at the time of biopsy and in none of the
patients with persistently normal ALT. Patients with normal
ALT who were biopsied had higher HBV DNA and higher ALT
than those not biopsied. Multivariate analysis showed that
low albumin at the time of biopsy and HBV DNA >5
log10 copies/mL were predictors of significant liver disease.
Significant liver disease is rare in patients with chronic HBV
and persistently normal ALT and liver histology of chronic
HBV infected patients with normal ALT cannot be generalized
to other patients with normal ALT that were not biopsied.
Keywords: HBV DNA, hepatitis B e antigen, liver fibrosis,
liver histology, normal ALT.
INTRODUCTION
Current treatment guidelines for hepatitis B recommend
antiviral therapy only for those with active/advanced liver
disease and high serum hepatitis B virus (HBV) DNA levels
[1–3]. Liver biopsy is an invasive procedure and its accuracy
in grading or staging liver disease is limited by sampling
error [4]; therefore, treatment decision is generally made
based on alanine aminotransferase levels (ALT).
Traditionally, persons with ALT values within the normal
range were considered to have ‘‘healthy’’ livers. However,
several studies found that persons with ALT values that were
0.5–1 times the upper limit of normal (·ULN) had a higher
risk of mortality from liver disease or cirrhosis complications
than those with ALT <0.5 · ULN [5–8]. Furthermore, sev-
eral studies showed that moderate inflammation and/or
advanced fibrosis can be found in 28%–37% of patients with
chronic HBV infection who had persistently normal ALT
[9–14]. These new data have prompted some experts to
recommend the abandonment of ALT as a criterion in the
determination of candidacy for HBV treatment [7,8,10,15].
It has also been suggested that the designated upper limits of
normal for ALT values in most diagnostic laboratories are
erroneously high and the correct upper limit of normal
should be 30 U/L for men and 19 U/L for women [16]. Using
these lower cut-offs, several studies have found that signifi-
cant liver disease can be found in 13%–30% of hepatitis B
patients with persistently normal ALT [10,12,14].
These studies indicate that hepatitis B patients with per-
sistently normal ALT can have significant liver disease on
liver histology and can experience liver-related mortality.
However, there are several limitations to these studies. Many
studies included small numbers of patients, and persistently
normal ALT was often based on two ALT values that were
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within a few months of each other. The definition of signif-
icant liver disease was not standardized and varied from
fibrosis only (score of ‡2 on a scale of 0–4) or inflammation
only (score of ‡2 on a scale of 0–3 or 0–4) or a combination
of inflammation and fibrosis [9–14]. In some studies, only
patients with persistently normal ALT and high serum HBV
DNA levels were biopsied; therefore, the results cannot be
generalized to all patients with normal ALT. Finally, most
studies did not report how many patients with persistently
normal ALT were not biopsied, raising the possibility of
selection bias.
In this study, we aimed (i) to determine the percentage of
patients with chronic HBV infection seen at a tertiary
referral centre that underwent liver biopsy and to compare
the characteristics of patients who underwent a liver biopsy
versus those who did not, (ii) to determine the liver histology
in the patients who were biopsied and the factors associated
with significant liver disease and (iii) to compare the utility of
ALT and HBV DNA patterns vs. values at the time of biopsy
in predicting significant liver disease.
MATERIALS AND METHODS
Clinical and laboratory data of 871 adult hepatitis B surface
antigen (HBsAg)-positive patients seen at the liver clinic of
the University of Michigan Health System between December
31, 1997 and December 31, 2007 were retrospectively re-
viewed. The protocol was approved by the Institution Review
Board. One hundred and twenty-eight patients were ex-
cluded for the following reasons: 28 had acute hepatitis B,
42 had hepatitis C virus co-infection, 18 had human
immunodeficiency virus co-infection, 23 had undergone
liver transplantation, 9 had decompensated cirrhosis, 1 had
hepatocellular carcinoma (HCC) and 7 had other malig-
nancies. The remaining 743 patients were included in this
analysis.
Patient demographics (age, gender, race), known duration
of HBV infection, HBV markers [hepatitis B e antigen
(HBeAg), hepatitis B e antibody (anti-HBe), HBV DNA];
hepatic panel [albumin, aspartate aminotransferase (AST),
ALT, total bilirubin (TB), and alkaline phosphatase (AP)];
complete blood count (CBC); and prothrombin time/inter-
national normalized ratio (INR) from the time of presenta-
tion to the time of the first liver biopsy (for those who
underwent at least one liver biopsy) or the last follow-up (for
those who had not undergone a liver biopsy) were recorded.
For both groups of patients, data were censored at the time
antiviral treatment was initiated.
Definition of ALT and HBV DNA Pattern
To determine the correlation between serial ALT and serial
HBV DNA levels and liver histology, a subset of patients with
at least three ALT values minimum 3 months apart during a
1-year period before having a liver biopsy at our hospital
were analyzed. Patients who had not undergone a liver
biopsy and had at least three HBV DNA and ALT values
during the last year of follow-up and a comparable duration
of follow-up as those who were biopsied served as controls.
Patients who underwent a liver biopsy prior to referral to our
hospital were excluded from this analysis.
Patients were classified as having ALT patterns that were
persistently normal (all values within the normal range),
intermittently abnormal (some values within the normal
range and at least 1 value above the upper limit of normal)
or persistently abnormal (all values above the upper limit of
normal). Normal ALT was defined based on our laboratory
reference value of 40 U/L unless specified otherwise; for
these other analyses, the recently proposed new upper limits
of 30 U/L for men and 19 U/L for women were used.
HBV DNA patterns were classified into persistently low
(all values <105 copies/mL), fluctuating (some values
<105 copies/mL and at least 1 value >105 copies/mL) or
persistently high (all values ‡105 copies/mL). Serum HBV
DNA was quantified by hybridization assays with a lower
limit of detection of 5 pg/mL (roughly 750 000 copies/mL)
prior to January 2000, commercially available polymerase
chain reaction assays - Amplicor HBV monitor test (Roche
Diagnostics, Indianapolis, IN, USA) with a lower limit of
detection of 200–1000 copies/mL between 2000 and 2005,
and real-time polymerase chain reaction assays, COBAS
TaqMan HBV (Roche Diagnostics) with a lower limit of
detection of 29 IU/mL (150 copies/mL) from July 2005 on-
wards. Baseline HBV DNA tested after January 2000 was
classified as <3 log10, 3–5 log10 and >5 log10 copies/mL,
and as <5 log10 (undetectable) and >5 log10 (detectable)
copies/mL for patients tested before January 2000.
Interpretation of liver histology
A single pathologist (BM) who was blinded to patient
information reviewed each biopsy performed at our institute
and graded the biopsies using the Knodell histology activity
index (HAI) (range, 0–18) and the Ishak fibrosis stage
(range, 0–6) [17]. Patients were considered to have signifi-
cant liver disease if the HAI (necroinflammation components
only) was at least 7 and/or the fibrosis score was at least 3.
Statistical analyses
Continuous variables were expressed as mean ± SD, or
median and range. Serum HBV DNA was expressed as
log10 copies/mL. Laboratory values, such as ALT, that were
not normally distributed were expressed as a ratio of the upper
limit of normal. Categorical variables were expressed as
number and per cent. The Student t test or Mann–Whitney
test was used to compare continuous variables while the
Fishers exact or Chi-square test was used for categorical data.
In all cases, comparisons were two-tailed, and a P-value of
<0.05 was considered statistically significant.
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The following variables: demographics (gender, age, race);
laboratory values at the time of presentation (platelet, INR,
albumin, TB, AST, ALT, AP, HBV DNA) and at the time of
liver biopsy; ALT patterns; and HBV DNA patterns were
analysed to determine the predictors of significant liver dis-
ease. Variables (at presentation and at the time of biopsy)
with a P value <0.1 on univariate analysis were further
analysed by multivariate logistic regression to determine the
independent predictors of significant liver disease in the 105
patients whose biopsies were reviewed. For the analysis of
predictors of significant liver disease in the 74 patients with
serial laboratory values prior to biopsy, only variables at the
time of biopsy with a P value <0.1 on univariate analysis,
ALT pattern and HBV DNA pattern were used. The data
analyses were performed using SPSS software version 14
(SPSS Chicago, IL, USA).
RESULTS
Characteristics of patients at the time of presentation
Of the 743 patients studied, 210 were Caucasians, 414
Asian Americans, 65 African Americans, 6 Hispanics, 4
Native Americans and 4 were mixed race. The race of the
remaining 40 patients was not identified. Slightly more than
half of the patients were men (56.4%) and the mean age of
the entire cohort was 43.1 ± 11.4 years. At presentation,
34% of the patients were HBeAg positive, 79% had detect-
able serum HBV DNA and 37% had HBV DNA >5
log10 copies/mL. Half of the patients had ALT above the
upper limit of normal based on our hospital laboratory and
80% had ALT higher than the new proposed upper limit of
normal.
Baseline characteristics of patients who had or
had not undergone a liver biopsy
A total of 193 (26.0%) patients had undergone at least one
liver biopsy (110 at our centre (UM) and 83 at an outside
hospital prior to referral). The mean interval between the
outside biopsy and referral to our hospital was
17.5 ± 18.4 months and the median was 12 (1–84)
months. Among the patients who were biopsied at our
centre, the mean follow-up between presentation and liver
biopsy was 17.9 ± 18.9 months [median 12 (1–108)
months]. The mean follow-up of the 550 patients who had
not undergone any liver biopsy was 30.2 ± 28.3 months
[median 18 (1–120)].
Compared to the patients who have not undergone a liver
biopsy, those who had undergone a liver biopsy prior to or
after referral were older, more likely to be men and to be
Caucasians. Patients who had undergone a liver biopsy were
more often HBeAg positive and had lower platelet count, and
higher AP, bilirubin, ALT, AST and HBV DNA level
(Table 1).
Liver biopsies were performed in 42/357 (11.8%) patients
who had normal ALT at presentation and in 69/120
(57.5%) patients who had ALT >2 · ULN based on our
hospital definition of the normal range, and in 17/144
(11.8%) patients who had normal ALT based on the new
proposed lower cut-off values. Liver biopsies were performed
in 20/179 (11.2%), 36/194 (18.6%) and 94/220 (42.7%)
patients who had serum HBV DNA <3, 3–5 and >5
log10 copies/mL at presentation, respectively.
There was no difference in demographics or laboratory
parameters between the patients who underwent a liver
biopsy at our hospital and those who had a liver biopsy
before referral to our hospital.
ALT and HBV DNA patterns during follow-up
Three hundred and fifteen (42.4%) patients including 74
who were biopsied at our hospital were included in this
analysis. Among the 74 patients who had undergone a liver
biopsy, the mean number of ALT and HBV DNA values prior
to the biopsy was 6.8 ± 4.5, [median 6 (3–25)] and the
mean follow-up between presentation and the first liver
biopsy was 25.1 ± 19.7 months [median 15 (range 12–
108)]. The mean number of ALT and HBV DNA values for
the remaining 241 patients was 7.1 ± 4.8, [median 6
(3–25)] and the mean follow-up from the time of presentation
to data censoring (most recent follow-up visit or initiation
of antiviral treatment) was 27.9 ± 20.1 months [median
17 (range 12–110)].
Of these 315 patients, 33.7% patients had persistently
normal ALT, 43.1% had intermittently abnormal ALT and
23.2% had persistently abnormal ALT (Table 2). The factors
associated with persistently normal ALT were higher platelet
count at baseline and HBV DNA persistently below 5
log10 copies/mL during follow-up. Only 6.7% of the patients
had persistently normal ALT if the proposed new upper
limits of normal were used.
One hundred and fifty-three (48.5%) patients had HBV
DNA persistently below 5 log10 copies/mL, 50 (15.9%) had
HBV DNA levels persistently above 5 log10 copies/mL, and
the remaining 112 (35.6%) had fluctuating HBV DNA levels
(Table 2). Factors associated with HBV DNA persistently
below 5 log10 copies/mL included being HBeAg negative at
presentation and having persistently normal or intermit-
tently normal ALT pattern during follow-up.
ALT and HBV DNA Patterns in Patients Who Had or
Had not Undergone a Liver Biopsy
Compared to the 241 patients who have not been biopsied,
the 74 patients who had undergone a liver biopsy were more
likely to be men and to be HBeAg positive and had lower
platelet count and higher alkaline phosphatase, bilirubin,
AST, ALT and HBV DNA at presentation and at the time
of the biopsy (Table 2). Of the 106 patients who had
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persistently normal ALT, only 5 (4.7%) had undergone a
liver biopsy compared to 59 (53.4%) of 73 patients who had
persistently abnormal ALT (Fig. 1). None of the 21 patients
with persistently normal ALT based on the proposed new
cut-off had been biopsied. Among the 153 patients with HBV
DNA persistently <5 log10 copies/mL, 8 (5.2%) had under-
gone a liver biopsy compared to 26 (52%) of 50 with HBV
DNA persistently >5 log10 copies/mL (Fig. 1). When both
ALT and HBV DNA patterns were considered, only 1 (1.3%)
of 77 patients who had persistently normal ALT and HBV
DNA persistently <5 log10 copies/mL had undergone a liver
biopsy compared to 1 of 7 (14.3%) patients who had
persistently normal ALT and HBV DNA persistently >5
log10 copies/mL.
Factors associated with performance of liver biopsy
in patients with normal ALT
Among 153 patients with normal ALT at presentation, 13
(8.5%) patients had undergone a liver biopsy. The only factor
Table 1 Baseline characteristics of all patients













No. of patients 110 (14.8) 83 (11.2) 193 (26.0) 550 (74.0)
Age, years 44.5 ± 11.3 45.3 ± 13.2 44.9 ± 12.1 42.3 ± 13.5 0.01 0.06
Gender (male) 85 (77.3) 62 (74.1) 147 (76.2) 272 (49.5) <0.001 <0.001
Race
Caucasian 37 (33.6) 38 (45.8) 75 (38.9) 135 (24.5) 0.01 0.04
Asian 59 (53.6) 33 (39.8) 92 (47.7) 322 (58.5)
African American 9 (8.2) 4 (4.8) 13 (6.7) 52 (9.5)
Hispanic 1 (0.9) 0 (0) 1 (0.5) 5 (0.9)
Other 0 (0) 3 (3.6) 3 (1.5) 5 (0.9)
Unknown 4 (3.6) 5 (6) 9 (4.7) 31 (5.7)
BMI 26.1 ± 5.2 25.3 ± 4.5 25.8 ± 5.0 25.1 ± 4.9 0.13 0.08
Laboratory values at Baseline
Platelet (K per mm3) 197 ± 595 203 ± 705 199 ± 36 230 ± 62 <0.001 <0.001
INR 1.0 ± 0.1 1.0 ± 0.1 1.0 ± 0.1 1.0 ± 0.1 0.08 0.14
Albumin (g/dL) 4.1 ± 0.5 4.2 ± 0.4 4.1 ± 0.5 4.2 ± 0.4 0.06 0.02
AP (U/L) 92 ± 40 92 ± 56 92 ± 46 74 ± 37 <0.001 <0.001
Total bilirubin (mg/dL) 0.8 ± 0.6 0.8 ± 0.5 0.8 ± 0.6 0.6 ± 0.4 0.002 0.007
AST (U/L) 97 ± 138 92 ± 213 162 ± 168 33 ± 32 <0.001 <0.001
ALT (U/L) 156 ± 253 108 ± 177 136 ± 225 50 ± 69 <0.001 <0.001
Hospital laboratory reference range
<1 · ULN 22 (20) 20 (24.1) 42 (21.8) 315/524 (60.1) <0.001 <0.001
1–2 · ULN 45 (40.9) 37 (44.6) 79 (42.4) 158/524 (30.1)
>2 · ULN 43 (39.1) 26 (31.3) 69 (35.8) 51/524 (9.8)
New criteria
<1 · ULN 8 (7.3) 9 (10.8) 17 (8.8) 127/524 (24.2) 0.01 <0.001
% HBeAg positive 47/108 (43.5) 34/76 (44.7) 81/184 (44) 140/464 (30.2) 0.001 0.008
% HBV DNA detectable 85/96 (88.5) 46/54 (85.2) 131/150 (87.3) 339/443 (76.5) 0.005 0.009
HBV DNA (log10 copies/mL) 5.8 ± 2.7 5.2 ± 2.8 5.6 ± 2.7 3.8 ± 2.8 <0.001 <0.001
<3 11/96 (11.5) 9/54 (16.7) 20/150 (13.3) 159/443 (35.9) <0.001 <0.001
3–5 22/96 (22.9) 14/54 (25.9) 36/150 (24) 158/443 (35.7)
>5 63/96 (65.6) 31/54 (57.4) 94/150 (62.7) 126/443 (28.4)
Results expressed as number (%) or mean ± SD unless specified otherwise. UM, University of Michigan Health System; No,
number; BMI, body mass index; INR, prothrombin time/international normalized ratio; AP, alkaline phosphatase; AST,
aspartate aminotransferase; ALT, alanine aminotransferase; ULN, upper limit of normal; HBeAg, hepatitis B e antigen; HBV,
hepatitis B virus. *Comparison between patients who had or had not undergone biopsy. **Comparison patients who underwent
biopsy at our centre (UM) and patients who had not undergone biopsy. Proposed new upper limits of 19 U/L for women
30 U/L for men.
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Table 2 Characteristics of patients with serial laboratory values
Had biopsy No biopsy Total P-value
Number of patients 74 241 315
Age 44.2 ± 10.9 44.0 ± 13.7 44.1 ± 13.1 0.89
Gender (male) 57 (77) 123 (51) 180 (57.1) <0.001
Race
Caucasian 23 (31.1) 50 (20.8) 73 (23.2) 0.05
Asian 44 (59.5) 156 (64.8) 200 (63.5)
African American 4 (5.3) 23 (9.5) 27 (8.6)
Hispanic 1 (1.4) 2 (0.8) 3 (0.9)
Other 0 (0) 2 (0.8) 2 (0.6)
Unknown 2 (2.7) 8 (3.3) 10 (3.2)
BMI 26.0 ± 5.0 25.1 ± 5.1 25.3 ± 5.1 0.19
Laboratory values at Baseline
Platelet (K per mm3) 202 ± 60 229 ± 61 220 ± 62 0.003
INR 1.0 ± 0.1 1.0 ± 0.1 1.0 ± 0.1 0.48
Albumin (g/dL) 4.1 ± 0.4 4.2 ± 0.4 4.2 ± 0.4 0.21
AP (U/L) 91 ± 41 74 ± 36 79 ± 38 0.002
Total bilirubin (mg/dL) 0.7 ± 0.5 0.6 ± 0.3 0.6 ± 0.4 0.007
AST (U/L) 81 ± 110 33 ± 33 48 ± 71 <0.001
ALT (U/L) 139 ± 234 52 ± 71 72 ± 134 <0.001
Hospital laboratory reference range
<1 · ULN 13 (17.6) 140 (58.1) 153 (48.5) <0.001
1–2 · ULN 34 (45.9) 73 (30.3) 107 (34)
>2 · ULN 27 (36.5) 28 (11.6) 55 (17.5)
New criteria
<1 · ULN* 4 (5.4) 42 (17.4) 46 (14.6) <0.001
% HBeAg positive 32 (43.2) 54/218 (22.4) 86/292 (27.3) 0.003
% HBV DNA detectable 65 (87.8) 179 (74.3) 241 (76.5) 0.09
HBV DNA (log10 copies/mL) 5.8 ± 2.7 3.9 ± 3.0 4.4 ± 3.0 <0.001
<3 8 (10.8) 93 (38.6) 101 (32.1) <0.001
3–5 19 (25.7) 69 (28.6) 88 (27.9)
>5 47 (63.5) 79 (32.8) 126 (40)
Laboratory values at the Time of Biopsy
Platelet (K per mm3) 199 ± 63 225 ± 58 218 ± 60 0.002
INR 1.0 ± 0.1 1.0 ± 0.1 1.0 ± 0.1 0.24
Albumin (g/dL) 4.2 ± 0.4 4.3 ± 0.4 4.3 ± 0.4 0.01
Total bilirubin (mg/dL) 0.7 ± 0.3 0.7 ± 1.3 0.7 ± 1.2 0.74
AP (U/L) 86 ± 30 70 ± 22 74 ± 25 <0.001
AST (U/L) 67 ± 64 28 ± 12 37 ± 36 <0.001
ALT (U/L) 111 ± 126 42 ± 30 58 ± 73 <0.001
Hospital laboratory reference range
<1 · ULN 8 (10.9) 156 (64.7) 164 (52.1) <0.001
1–2 · ULN 36 (48.6) 61 (25.3) 97 (30.8)
>2 · ULN 30 (40.5) 24 (10) 54 (17.1)
New criteria
<1 · ULN* 1 (1.4) 73 (30.3) 74 (23.5) <0.001
% HBeAg positive 27 (36.5) 28/156 (17.9) 55/230 (23.9) 0.002
% HBV DNA detectable 74 (100) 182 (75.5) 256 (81.3) <0.001
HBV DNA (log10 copies/mL) 6.3 ± 2.1 3.2 ± 2.2 3.9 ± 2.5 <0.001
<3 3 (4.1) 97 (40.2) 100 (31.7) <0.001
3–5 15 (20.3) 98 (40.7) 113 (35.9)
>5 56 (75.6) 46 (19.1) 102 (32.4)
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associated with the performance of a liver biopsy was higher
serum HBV DNA at presentation (4.7 vs 3.2 log10 copies/mL,
P = 0.04) (Table 3). Eight patients had normal ALT at the
time of biopsy. Compared to the other 156 patients who had
normal ALT after a similar duration of follow-up and had not
had a liver biopsy, the patients who were biopsied had higher
serum ALT (34 vs 26 U/L, P = 0.006) and HBV DNA values
(5.2 vs 3.1 log10 copies/mL, P = 0.005). Of the 106 patients
with persistently normal ALT, five had undergone a liver
biopsy and factors associated with performance of a liver
biopsy included Caucasian race, presence of HBeAg and
higher alkaline phosphatase, ALT and HBV DNA values at
the time of biopsy.
Inflammation and fibrosis scores on liver biopsies
Biopsy slides were available for review in 105 (95.5%) of
110 patients who had liver biopsies performed at our hos-
pital. The mean HAI and Ishak fibrosis scores were 4.8 ± 2.8
and 2.7 ± 2.0, respectively. Twenty-one (20%) patients had
cirrhosis (Ishak fibrosis 5 or 6). Fifty-nine (56.2%) patients
had significant liver disease – 10 patients (16.9%) had HAI
Table 2 (Continued)
Had biopsy No biopsy Total P-value
ALT pattern (Hospital laboratory reference range)
Persistently normal 5 (6.8) 101 (41.9) 106 (33.7) <0.001
Intermittently abnormal 30 (40.5) 106 (44) 136 (43.1)
Persistently abnormal 39 (52.7) 34 (14.1) 73 (23.2)
ALT pattern (new criteria)*
Persistently normal 0 (0) 21 (8.7) 21 (6.7) <0.001
Intermittently abnormal 16 (21.6) 85 (35.3) 101 (32.1)
Persistently abnormal 58 (78.4) 135 (56) 193 (61.3)
HBV DNA pattern (log10 copies/mL)
Persistently <5 8 (10.8) 145 (60.2) 153 (48.5) <0.001
Fluctuating 40 (54.1) 72 (29.8) 112 (35.6)
Persistently >5 26 (35.1) 24 (10) 50 (15.9)
BMI, body mass index; INR, prothrombin time/international normalized ratio; AP, alkaline phosphatase; AST, aspartate
aminotransferase; ALT, alanine aminotransferase; ULN, upper limit of normal; HBeAg, hepatitis B e antigen; HBV, hepatitis B
virus. Results expressed as number (%) or mean ± SD unless specified otherwise. *<1 · ULN based on proposed new upper
limits of 19 U/L for women 30 U/L for men.
Fig. 1 The percentage of patients who
underwent a liver biopsy at our hospital
according to ALT and HBV DNA pat-
terns. ALT, alanine aminotransferase;
HBV, hepatitis B virus.
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‡7 only, 27 patients (45.8%) had Ishak fibrosis score ‡3 only
and 22 patients (37.3%) had both HAI ‡7 and Ishak fibrosis
score ‡3. Compared to the patients who had milder liver
disease, those who had significant liver disease had higher
AST, ALT and HBV DNA at presentation, and higher AST,
ALT and HBV DNA, and lower albumin at the time of biopsy
(Table 4).
Significant liver disease was observed in 4 (20%) of the 20
patients who had normal ALT at presentation, in 2 of the 14
(14.3%) patients with normal ALT at the time of biopsy, and
in none of the five patients with persistently normal ALT.
(Fig. 2a). The mean HAI for the five patients with persis-
tently normal ALT was 1.8 ± 0.8, and the mean Ishak
fibrosis score was 0.6 ± 0.5. Significant liver disease was
Table 3 Factors associated with performance of a liver biopsy in patients with normal alanine aminotransferase
Had biopsy No biopsy Total P-value
Patients with Normal ALT at Presentation 13 140 153
Age 44.2 ± 10.5 42.5 ± 12.6 42.6 ± 12.4 0.57
Gender (Male) 7 (53.8) 60 (42.9) 67 (43.8) 0.76
Race
Caucasian 4 (30.7) 26 (18.6) 30 (19.6) 0.63
Asian 7 (53.9) 92 (65.7) 99 (64.7)
Other 2 (15.4) 22 (15.7) 24 (15.7)
Laboratory values at baseline
Platelet (K per mm3) 222 ± 91 232 ± 56 231 ± 60 0.14
ALT (U/L) 29 ± 8 28 ± 7 28 ± 7 0.60
Albumin (g/dL) 4.2 ± 0.4 4.1 ± 0.4 4.2 ± 0.4 0.56
AP (U/L) 78 ± 20 71 ± 22 72 ± 22 0.14
HBeAg positive 6 (46.2) 34/133 (25.6) 40/139 (28.8) 0.18
HBV DNA (log10 copies/mL) 4.7 ± 2.8 3.2 ± 2.8 3.3 ± 2.9 0.04
Patients with Normal ALT at the Time of Liver Biopsy 8 156 164
Age 44 ± 8.3 42.5 ± 12.6 42.6 ± 12.4 0.5
Gender (Male) 4 (50) 75 (48.1) 79 (48.2) 0.6
Race
Caucasian 4 (50) 26 (16.7) 30 (18.3) 0.07
Asian 2 (25) 106 (67.9) 108 (65.9)
Other 2 (25) 24 (15.4) 26 (15.8)
Laboratory values at the time of biopsy
Platelet (K per mm3) 199 ± 59 230 ± 59 228 ± 59 0.2
ALT (U/L) 34 ± 6 26 ± 8 26 ± 8 0.006
Albumin (g/dL) 4.3 ± 0.4 4.3 ± 0.4 4.3 ± 0.4 0.91
AP (U/L) 76 ± 22 69 ± 21 69 ± 21 0.26
HBeAg positive 3 (37.5) 18/105 (17.1) 21/113 (18.6) 0.17
HBV DNA (log10 copies/mL) 5.2 ± 1.3 3.1 ± 2.1 3.2 ± 2.2 0.005
Patients with Persistently Normal ALT 5 101 106
Age 43 ± 11 43 ± 13 43 ± 12.4 0.84
Gender (Male) 3 (60) 40 (39.6) 43 (40.6) 0.39
Race
Caucasian 3 (60) 19 (18.8) 22 (20.8) 0.04
Asian 0 (0) 65 (64.4) 65 (61.3)
Other 2 (40) 17 (16.8) 19 (17.9)
Laboratory values at the time of biopsy
Platelet (K per mm3) 194 ± 71 230 ± 59 228 ± 60 0.33
ALT (U/L) 34 ± 6 29 ± 8 29 ± 8 0.009
Albumin (g/dL) 4.2 ± 0.4 4.2 ± 0.4 4.2 ± 0.4 0.49
AP (U/L) 89 ± 16 69 ± 23 70 ± 23 0.05
HBeAg positive 3 (60) 9/68 (13.2) 12/71 (16.9) 0.03
HBV DNA (log10 copies/mL) 5.5 ± 1.3 2.8 ± 2.1 3.0 ± 2.2 0.006
ALT, alanine aminotransferase; AP, alkaline posphatase; HBeAg, hepatitis B e antigen; HBV, hepatitis B virus. Results
expressed as number (%) or mean ± SD unless specified otherwise.
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Table 4 Comparison of patients with or without significant liver disease
Characteristics of biopsied patients
Not significant liver disease Significant liver disease P-value
Number of patients 46 (43.9) 59 (56.1)
Age 44.4 ± 10.9 44.9 ± 11.8 0.84
Gender (male) 38 (82.6) 45 (76.3) 0.43
Race
Caucasian 12 (26.1) 25 (42.4) 0.13
Asian 28 (60.8) 28 (47.4)
African American 4 (8.7) 4 (6.8)
Hispanic 1 (2.2) 0 (0)
Other/Unknown 1 (2.2) 2 (3.4)
BMI 25.6 ± 4.2 26.5 ± 5.9 0.61
Laboratory values at Baseline
Platelet (K per mm3) 201 ± 60 191 ± 58 0.41
INR 1.0 ± 0.1 1.0 ± 0.1 0.79
Albumin (g/dL) 4.1 ± 0.7 4.0 ± 0.4 0.21
AP (U/L) 88 ± 37 94 ± 42 0.45
Total bilirubin (mg/dL) 0.8 ± 0.7 0.8 ± 0.4 0.90
AST (U/L) 72 ± 130 117 ± 144 <0.001
ALT (U/L) 90 ± 153 201 ± 292 <0.001
Hospital laboratory reference range
<1 · ULN 16 (34.8) 4 (6.8) 0.001
1–2 · ULN 21 (45.6) 23 (39.0)
>2 · ULN 9 (19.6) 32 (54.2)
New criteria
<1 · ULN* 7 (15.2) 0 (0) 0.002
HBeAg positive 18 (39.1) 25 (42.4) 0.69
HBV DNA (log10 copies/mL) 5.0 ± 2.6 6.5 ± 2.6 0.005
<3 9/45 (20) 4/53 (7.6) 0.007
3–5 15/45 (33.3) 7/53 (13.2)
>5 21/45 (46.7) 42/53 (79.2)
Laboratory values at the Time of Biopsy
Platelet (K per mm3) 202 ± 58 192 ± 64 0.31
INR 1.0 ± 0.1 1.0 ± 0.1 0.73
Albumin (g/dL) 4.3 ± 0.4 4.0 ± 0.4 0.003
AP (U/L) 84 ± 27 88 ± 35 0.49
Total bilirubin (mg/dL) 0.7 ± 0.3 0.7 ± 0.2 0.36
AST (U/L) 56 ± 36 83 ± 72 0.002
ALT (U/L) 86 ± 70 122 ± 132 <0.001
Hospital laboratory reference range
<1 · ULN 12 (26.1) 2 (3.4) 0.001
1–2 · ULN 18 (39.1) 28 (47.4)
>2 · ULN 16 (34.8) 29 (49.2)
New criteria
<1 · ULN* 2 (4.3) 2 (3.4) 0.98
HBeAg positive 16 (34.8) 21 (35.6) 0.97
HBV DNA (log10 copies/mL) 5.5 ± 2.1 6.9 ± 1.8 <0.001
<3 4 (8.7) 1 (1.7) 0.005
3–5 14 (30.4) 6 (10.2)
>5 28 (60.9) 52 (88.1)
BMI, body mass index; INR, prothrombin time/international normalized ratio; AP, alkaline phosphatase; AST, aspartate ami-
notransferase; ALT, alanine aminotransferase; ULN, upper limit of normal; HBeAg, hepatitis B e antigen; HBV, hepatitis B virus.
Results expressed as number (%) or mean ± SD unless specified otherwise. *<0.5 · ULN: the recently proposed new upper limits of
19 IU/L for women 30 IU/L for men.
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(a)
(b)
Fig. 2 The percentage of patients with
Knodell inflammation ‡7 and/or Ishak
fibrosis score ‡3 according to (a) ALT
patterns and (b) HBV DNA patterns.
ALT, alanine aminotransferase; HBV,
hepatitis B virus.
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observed in 11 of the 35 (31.4%) patients with HBV DNA <5
log10 copies/mL at presentation, in 7 of the 25 (28%)
patients with HBV DNA <5 log10 copies/mL at the time
of biopsy and in 1 of the 8 (12.5%) patients who had HBV
DNA persistently <5 log10 copies/mL (Fig. 2b).
Predictors of significant liver disease
Univariate analysis of predictors of significant liver disease in
the 105 patients whose biopsies were reviewed found that
AST at baseline, ALT at baseline, HBV DNA at baseline,
albumin at the time of biopsy, AST at the time of biopsy, ALT
at the time of biopsy and HBV DNA at the time of biopsy
were significant. Multivariate analysis showed that low
albumin (P = 0.01, OR 0.18, 95% CI 0.05–0.69) and high
HBV DNA level (P = 0.05, OR 1.30, 95% CI 1.01–1.70) at
the time of liver biopsy were independent predictors of sig-
nificant liver disease. When the analysis was limited to the
74 patients who had serial laboratory values prior to biopsy,
albumin at the time of biopsy, ALT pattern (persistently
normal ALT vs. intermittently or persistently abnormal ALT)
and HBV DNA pattern (persistently <5 log10 copies/mL vs
intermittently or persistently >5 log10 copies/mL) were sig-
nificant on univariate analysis. Multivariate analysis found
that the independent predictors of significant liver disease
were low albumin at the time of liver biopsy (P = 0.02, OR
0.17, 95% CI 0.04–0.71) and HBV DNA pattern: intermit-
tently or persistently >5 log10 copies/mL (P = 0.04, OR
9.82, 95% CI 1.10–48.84) while ALT pattern during follow-
up was not.
DISCUSSION
In this study of 743 patients with chronic HBV infection
followed for a median of 16 months (range 1–120), only
193 (26%) had undergone a liver biopsy (110 at our
hospital and 83 at an outside hospital prior to referral). As
expected, patients who had laboratory values indicative of
more active or advanced liver disease (lower platelet count,
and higher bilirubin, AST, ALT and alkaline phosphatase),
and more active HBV replication (higher HBV DNA and
presence of HBeAg) were more likely to have undergone a
liver biopsy. Our study also found that men, older patients
(>45 years) and Caucasians were more likely to have
undergone a liver biopsy. Male gender and older age (a
surrogate for the duration of infection) have been shown in
many studies to be associated with increased risk of ad-
vanced fibrosis, cirrhosis and HCC [18–21]. The finding that
Caucasians were more likely than Asians to have had a liver
biopsy may reflect the general reluctance of Asian patients to
undergo liver biopsies rather than differences in indications
for liver biopsy. A review of the HBV DNA and ALT values of
patients who were biopsied found that 21% of those biopsied
in the latter 5 years versus 6% of those biopsied in the first
5 years of the study had HBV DNA 3–5 log10 copies/mL or
persistently normal ALT indicating that over time lower
cutoffs for HBV DNA and ALT were used as criteria for liver
biopsies. This change in practice is likely a result of recent
data showing that HBV DNA levels ‡4 log10 copies/mL are
associated with increased risk of cirrhosis and HCC and
normal ALT may be associated with significant liver disease.
Significant liver disease as defined by Knodell HAI of at
least 7 and/or Ishak fibrosis score of at least 3 was observed
in 56.1% of patients. The vast majority (83%) of these
patients had advanced fibrosis with or without significant
inflammation and only 17% was classified as having signif-
icant liver disease based on necroinflammation alone. The
high percentage of patients with advanced fibrosis is likely
related to the older age of the patients, mean age of the
patients biopsied was 45 . Compared to patients who had
milder liver disease, patients with significant liver disease
had higher AST, ALT and HBV DNA at presentation, and
higher AST, ALT and HBV DNA, and lower albumin at the
time of biopsy. Multivariate analysis found that low albumin
at the time of liver biopsy and high HBV DNA during follow-
up and at the time of biopsy were predictors of significant
liver disease. These data support findings from other studies
showing that ALT is not an accurate predictor of liver his-
tology [9–11]. In this study, when ALT and HBV DNA at the
time of biopsy and ALT and HBV DNA patterns during fol-
low-up were analysed, HBV DNA levels intermittently or
persistently higher than 5 log10 copies/mL was the only
predictor of significant liver disease. This finding confirmed
previous studies showing an association between high HBV
DNA level and cirrhosis [22,23].
As in other studies, significant liver disease was found in
some patients with normal ALT: 20% of patients who had
normal ALT at presentation and 14% of those who had
normal ALT at the time of biopsy and none of those with
persistently normal ALT. The percentage of patients with
normal ALT and significant liver disease in this study was
lower compared to 28%–37% in other studies [9–14]. Dif-
ferences in characteristics of patients who were biopsied as
well as variations in histological assessment and definition of
significant liver disease may account for some of the dis-
crepancies. A more important factor may be related to the
long duration of normal ALT before the biopsy was per-
formed. Persistently normal ALT was defined as 2–3 normal
ALT values over a 6- month period in many previous stud-
ies. The 5 patients with persistently normal ALT that were
biopsied in this study had 5–25 normal ALT values over a
period of 20–108 months prior to the biopsy. This long
duration of normal ALT values may explain why none of
them had significant liver disease.
A major limitation of previous studies is the lack of
information on the patients who were not biopsied. Thus,
there may be a bias regarding which patients with normal
ALT were selected for liver biopsies. In this study, a liver
biopsy was performed in only 13.3% of patients who had
normal ALT at presentation, 5% of those with normal ALT at
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the time of biopsy (or after a comparable duration of follow-
up) and 5% of those with persistently normal ALT during
follow-up. Furthermore, only 6.3% of patients who had
normal ALT at presentation, 1.5% of those with normal ALT
at the time of biopsy and none of patients with persistently
normal ALT had undergone a liver biopsy, if the proposed
new upper limits of normal were used. More importantly, the
patients with normal ALT who underwent a liver biopsy
differed from those who have not had a liver biopsy in being
older, had higher HBV DNA and had higher though normal
ALT values, all of which had been shown in this study as
well as in other studies to be associated with significant liver
disease [8,11,13]. Therefore, liver histology of patients with
normal ALT cannot be generalized to other patients with
normal ALT that were not biopsied.
One limitation of this study is the small number of patients
biopsied, in particular, the low number of patients with
normal ALT that were biopsied. This is offset by the strengths
of this study including the availability of data on patients not
biopsied, more stringent definition of persistently normal
ALT and serial serum HBV DNA values in patients who had
or had not undergone a biopsy.
In summary, in this large cohort of patients with
chronic HBV infection, only a quarter had undergone a
liver biopsy. Patients with laboratory values associated
with active or advanced liver disease were more likely to
be biopsied. This was also true among the patients with
normal ALT confirming the concern that liver histology in
patients with normal ALT may not be representative of
those who were not biopsied. In this study, significant
liver disease was found in 56.1% of patients overall, but in
only 14.3% of patients with normal ALT at the time of
biopsy and in none of those with persistently normal ALT.
The lower percentage of patients with normal ALT and
significant liver disease compared to previous studies may
be related to a longer duration in which ALT remained
normal. In conclusion, significant liver disease can be
found in patients with chronic HBV infection and normal
ALT particularly in those who are older, have high nor-
mal ALT, low albumin or high HBV DNA. Significant liver
disease is rare in patients with persistently normal ALT.
These findings support treatment recommendations based
on ALT values provided that older patients, those with
high HBV DNA or other laboratory values suggestive of
more advanced liver disease undergo further evaluation
with a liver biopsy [1].
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